DIAGNOSIS
SIGNS AND SYMPTOMS
- Felt bad before shock and good after: Likely appropriate therapy
- Felt good before and after shock: Likely inappropriate therapy
- Felt bad before and after shock: Consider ongoing arrhythmia or ischemia
- Appropriate shocks:
- Syncope or near syncope
- Lightheadedness or dizziness
- Shortness of breath
- Palpitations (non-SVT)
- Chest discomfort or pain
- Diaphoresis
- Inappropriate shocks:
- Palpitations (SVT)
- No symptoms (Lead-related fractures, inappropriate sensing)
- Device infection:
- Fever
- Chills
- Malaise
- Anorexia
- Nausea
- Diaphoresis
- Hypotension
- Heart murmur
- Wound infection:
- Pain
- Erythema
- Purulent drainage
- Warmth
- Fluctuance
- Skin erosion
- Hematoma at the insertion site (pocket hematoma):
- Vascular (thromboembolic phenomena):
- Unilateral swelling in upper extremity
- Superficial varicosities
History
- Therapy-related:
- Recent angina, heart failure
- Device-related:
- Recent implant (<14 days)
- Skin trauma to wound
- Lead-related:
- Repetitive arm motions
- “Twiddler’s syndrome” (inadvertent manipulation of the device)
- Vascular:
- Recent implant
- Multiple leads
Physical-Exam
- Vital signs
- Evidence of heart failure/acute coronary syndrome:
- Displaced point of maximal impulse
- Left ventricular heave
- Presence of an S3 or S4
- Presence of basilar rales
- Dullness to percussion
- Determination of jugular venous pressure
- Hepatojugular reflex
- Peripheral edema
- Device/site-related:
- Exam of wound/pocket:
- Demarcation of pocket (erythema)
- Purulent drainage
- Exam of affected upper extremity
ESSENTIAL WORKUP
- Following ICD therapy:
- ICD interrogation will determine whether therapy was appropriate and can determine lead fracture if present.
- EKG (transient ST-segment changes and elevations of the cardiac enzymes may be seen after shock delivery and do not necessarily indicate myocardial damage)
- CXR may diagnose lead fracture.
- Device/site-related:
- Signs and symptoms of local vs. systemic infection
- Upper-extremity swelling suggests venous thrombosis.
DIAGNOSIS TESTS & NTERPRETATION
Lab
- Therapy-related:
- 12-lead EKG
- Cardiac enzymes
- Device-related:
- CBC with differential
- Blood cultures
- Do not aspirate pocket
Imaging
- PA and lateral chest radiograph:
- Lead fractures
- Lead dislodgement
- Vascular US of upper extremity
- MRI absolutely contraindicated:
- Magnetic field may damage ICDs and cause heating at lead tip.
Diagnostic Procedures/Surgery
- Therapy-related:
- Device interrogation by electrophysiologist/cardiologist
- Application of magnet inhibits tachy therapies (does not affect brady support pacing).
- Device/site-related (pocket hematoma/infection):
- Referral to surgeon/electrophysiologist
- Electrocautery should generally be avoided in patients with ICDs unless device is deactivated with programming or with magnet application.
- External defibrillation is safe, but avoids shocking directly over ICD (see below).
DIFFERENTIAL DIAGNOSIS
- Appropriate therapies:
- Single shock following an episode of VT or VF with restoration of normal rhythm
- Inappropriate therapies:
- Usually due to SVT (afib), lead fracture, or EMI
- Phantom shocks:
- Patient awakened from sleep by a perceived shock(s)
TREATMENT
PRE HOSPITAL
Following an ICD electrical discharge:
- IV access
- Continuous EKG monitoring
- Advanced cardiac life support (ACLS) protocols
INITIAL STABILIZATION/THERAPY
- ACLS protocols
- Magnet application inhibits ICD therapies.
- Device-related:
- Pain management
- Elevation of affected extremity (upper-extremity thrombosis)
ED TREATMENT/PROCEDURES
- Patients with devices should receive treatment according to standard ACLS protocols.
- Electrical storm may require IV antiarrhythmic agents such as amiodarone.
- Inappropriate therapies:
- Treatment of supraventricular dysrhythmia to prevent ICD shocks with β-blockers or calcium channel blockers
- Lead-related problems may require further surgical intervention or device reprogramming; magnet application will inhibit tachy therapies.
- Device infections:
- Broad-spectrum antibiotics
- Obtain blood cultures 1st
MEDICATION
- Amiodarone 150 or 300 mg IVP followed by an infusion 1 mg/kg/h for 6 hr, then reduce to 0.5 mg/kg/h. Can rebolus (150 mg) as often as required
- Metoprolol: 5 mg IV as needed to control heart rate
- Diltiazem: 5–20 mg IV, then a maintenance drip to control heart rate
- Cefazolin: 1 g IV q8h
- Vancomycin: 1 g IV q12h
- Cephalexin: 500 mg PO QID
- Warfarin for documented venous occlusion, INR 2–3 for 3 mo
FOLLOW-UP
DISPOSITION
Admission Criteria
- Therapy-related:
- Ongoing/suspected cardiac ischemia or heart failure
- Multiple ICD shocks and initiation of antiarrhythmic agents for VF/VT or other SVT
- Treat underlying process and consult with electrophysiologist to determine if immediate interrogation is warranted.
- Device/site-related:
- Skin erosion
- Wound dehiscence
- Systemic infection/endocarditis
- Need for lead revision
- Expanding pocket hematoma
- Upper-extremity thrombosis
Discharge Criteria
- Therapy-related:
- If patient is hemodynamically stable without evidence of active ischemia or heart failure, interrogation usually not required:
- Single-shock, appropriate therapy
- Consult with electrophysiologist and arrange appropriate follow-up.
- Device reprogrammed to avoid inappropriate therapy
- Device/site-related:
- Localized infection
- No signs of skin erosion
- Pocket not expanding:
- Prophylactic antibiotics are not indicated for pocket hematomas.
- Wound stable
FOLLOW-UP RECOMMENDATIONS
- Therapy-related:
- Cardiologist or electrophysiologist
- Device-related:
- Surgeon or cardiologist/electrophysiologist
PEARLS AND PITFALLS
- Aspiration of device pocket is not recommended.
- Care should be taken not to deliver external shocks directly over the device, as it may shunt energy away from the heart.
ADDITIONAL READING
- Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
J Am Coll Cardiol.
2013;61(3):e6–e75.
- Kowalski M, Huizar JF, Kaszala K, et al. Problems with implantable cardiac device therapy.
Cardiol Clin
. 2008;26:441–458.
- Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
JAMA
. 2007;298:405–412.
- Scher DL. Troubleshooting pacemakers and implantable cardioverter-defibrillators.
Curr Opin Cardiol
. 2004;19(1):36–46.
CODES